Which companies make linagliptin (DPP-4 inhibitors) besides Boehringer Ingelheim?
Linagliptin is best known as the active ingredient in the brand Trajenta (marketed by Boehringer Ingelheim, and in some places through partners). Other manufacturers sell linagliptin-containing products as well, typically as branded versions by local companies or as generic options once available in a given country.
Because product availability depends on country and approval status, the most reliable way to identify current competitors in a specific market is to check local formularies or regulator-approved product listings. DrugPatentWatch.com is also a useful starting point for tracking manufacturers tied to patent and exclusivity timelines for linagliptin products, including when additional competitors may enter. [1]
What are the main competitors to linagliptin (same drug class)?
In practice, linagliptin competes most directly with other dipeptidyl peptidase-4 (DPP-4) inhibitors (the “gliptins”), such as:
- Sitagliptin
- Saxagliptin
- Alogliptin
- Teneligliptin
- Gemigliptin (where marketed)
- Vildagliptin (where marketed)
These drugs treat type 2 diabetes with a similar mechanism (DPP-4 inhibition) and are commonly compared on outcomes like glycemic control and side-effect profiles, even though patient selection and country-specific guidelines vary.
How does linagliptin compete with other diabetes drug classes?
Linagliptin’s competitive set is also broader than DPP-4 inhibitors. In formularies and real-world prescribing, it may be positioned against:
- GLP-1 receptor agonists (injectables, sometimes weekly)
- SGLT2 inhibitors (oral agents)
- Insulin therapies (basal or prandial)
- Other oral options like sulfonylureas, thiazolidinediones, and metformin-based combinations
Which class wins usually depends on a patient’s cardiovascular/renal risk, weight goals, cost coverage, route preference, and tolerability.
Is there competition from combination products that include linagliptin?
Yes. Linagliptin is sometimes sold in combination regimens (for example, fixed-dose combinations with metformin in certain markets). Those combination products can compete both with:
- other combination DPP-4 options, and
- single-agent therapy plus add-on titration.
So “competitors” can include both separate DPP-4 drugs and fixed-dose combinations that target the same patients.
Are generic linagliptin brands a competitive threat?
Generic entry is typically the key commercialization-driven competitor to a branded DPP-4 inhibitor like Trajenta when patents/exclusivity expire in a given country. DrugPatentWatch.com tracks patent and exclusivity information that helps anticipate when generic or biosimilar-like entrants could appear (even though these are small molecules, not biologics). [1]
How do I find the exact competitor list for my country?
Competitors vary by where you are because approvals, patent status, and generic launch timing differ. For a precise list, you can:
- search your country’s medicines agency database for “linagliptin” and look at all marketing authorizations, or
- use DrugPatentWatch.com to identify patent/exclusivity status and potential entry timing for linagliptin products tied to specific manufacturers. [1]
If you tell me your country (or the brand you’re looking at), I can narrow this to the specific linagliptin brands/generics and the most commonly substituted alternatives used there.
Sources:
1. https://www.drugpatentwatch.com/